RxDoctor Payments DataLook up a doctor →

Patrick Thurmond, DO

Cardiovascular Disease · Jackson, MSNPI 1275897670

Payments from drug & device makers

$10,503in general payments, 2019–2025

Across 399 payments — averaging $26.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$4K
  • Abiomed$1K
  • Inari Medical, Inc.$857
  • Novartis$716
  • Merck$590
  • Pfizer$484
  • plus $3K from 36 others

What the payments were for

  • Travel & lodging$1,83717%
  • Food & beverage$8,66683%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,503 in reported general payments places this provider in the 70th percentile of 144 cardiovascular disease providers in Mississippi.

See all cardiovascular disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$189,035
Medicare patients
805
Services billed
2,040

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban262$205,215
EntrestoSacubitril/Valsartan218$178,652
JardianceEmpagliflozin58$63,799
XareltoRivaroxaban77$62,538
FarxigaDapagliflozin Propanediol54$48,570
Repatha SureclickEvolocumab67$44,488
Praluent PenAlirocumab28$13,308
LokelmaSodium Zirconium Cyclosilicate12$9,606
BrilintaTicagrelor24$8,675
Repatha SyringeEvolocumab13$8,077
Metoprolol Succinate345$3,653
Rosuvastatin Calcium390$3,203
Ezetimibe97$1,610
ClopidogrelClopidogrel Bisulfate239$1,561
Carvedilol265$1,383

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$484$205,215262 claims
NovartisEntresto$716$178,652218 claims
AstraZenecaFarxiga, Lokelma, Brilinta$345$66,85190 claims
Boehringer IngelheimJardiance$187$63,79958 claims
Johnson & JohnsonXarelto$265$62,53877 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 144 cardiovascular disease providers in Mississippi.

Other cardiovascular disease in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →